ArticleEuropean urology open science2026
Anti-inflammatory Diet Before Diagnosis and Survival After Urologic Cancer: Findings from Two Swedish Prospective Cohorts.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dietary patterns with anti-inflammatory properties have been linked to lower risks of several chronic diseases and some cancers, but their impact on survival after cancer is less well understood. Objective: We assessed whether a higher prediagnostic Anti-Inflammatory Diet Index (AIDI) score was associated with all-cause mortality after urologic cancer diagnosis, with urologic cancer-specific mortality evaluated as a secondary end point. Design setting and participants: In the Cohort of Swedish Men and the Swedish Mammography Cohort, incident urologic cancers and deaths were identified through Swedish registers. AIDI was derived from food-frequency questionnaires (1997; 2009 in a subset) and defined as the assessment at least 2 yr before diagnosis, preferentially 2009 when available. Follow-up ran from diagnosis to death, emigration, or December 31, 2020. Outcome measurements and statistical analysis: Cox models estimated hazard ratios (HRs) per 1 standard deviation (SD) higher AIDI, adjusting for demographic factors, lifestyle, comorbidities, and total energy intake. Fine-Gray models assessed urologic cancer-specific mortality while accounting for death from other causes as a competing event. Results and limitations: Among 7686 patients with valid AIDI, 6609 had complete covariate data, including 4990 patients with prostate cancer. During follow-up, 3281 deaths occurred, including 1435 urologic cancer deaths. Each 1-SD higher AIDI was associated with lower all-cause mortality (HR = 0.91, 95% confidence interval [CI] = 0.88-0.95). Evidence for an association with urologic cancer-specific mortality was weak and borderline in cause-specific Cox models (HR = 0.95, 95% CI = 0.90-1.00) and was attenuated in competing-risk analysis (subdistribution HR = 0.97, 95% CI = 0.92-1.02). Conclusions: Higher prediagnostic AIDI was associated with lower all-cause mortality after urologic cancer diagnosis. Whether this reflects a causal effect of diet or residual confounding, healthy-lifestyle clustering, health care engagement bias, or differences in competing noncancer mortality requires further study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.